Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
Status:
Withdrawn
Trial end date:
2020-07-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate any preliminary evidence of anticancer activity of
pembrolizumab combined with either pemetrexed or abemaciclib when used following surgery and
before standard therapy with radiation and temozolomide in patients with newly diagnosed high
grade glioma.
Additional aims of the study are to:
- Find out the side effects (good and bad) of pembrolizumab combined with pemetrexed or
abemaciclib;
- • Evaluate tumor characteristics by collecting brain tumor tissue samples.
- Measure the amount of pembrolizumab, pemetrexed, and/or abemaciclib that gets in the
body by collecting blood and cerebrospinal fluid.
- Look at biomarkers (biochemical features that can be used to measure the progress of
disease or the effects of a drug) in blood and cerebrospinal fluid if available.